
Diamyd Medical Investor Relations Material
Latest events

Q3 2025
Diamyd Medical

Q3 2025
25 Jun, 2025

Company Presentation
15 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Diamyd Medical
Access all reports
Diamyd Medical AB is a biotechnology company headquartered in Stockholm, Sweden, specializing in the development of immune modifying therapies for diabetes. The company is actively engaged in the pharmaceutical development field, focusing on two innovative disease-modifying drugs: Diamyd, an antigen-specific immunotherapy, and Remygen, an oral regenerative and immunomodulatory therapeutic. These drugs are undergoing clinical trials and are designed to address the underlying causes of diabetes, including dysfunction and loss of the pancreas's insulin-producing cells. Diamyd Medical operates a manufacturing facility in Umeå and leverages a global network of clinics, researchers, and production units for its development efforts. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.
Key slides for Diamyd Medical


Company Presentation
Diamyd Medical


Corporate Presentation
Diamyd Medical
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
DMYD
Country
🇸🇪 Sweden